Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

AZN vs CING: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AZN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–0 Matrix Metrics)

AZN Overall Winner 6-Pillar Tally: AZN 5 – 1 CING Matrix Metrics: AZN 9 – 0 CING

As of Nov 17, 2026, AstraZeneca PLC (AZN) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AZN carries a Unified Composite Score of 44.8/100 (HOLD) at $182.62 (16.3x Forward P/E, 25.8% operating margin), whereas CING carries 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: AZN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.3); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AZN vs CING
AZN NASDAQ Head-to-Head Winner
AstraZeneca PLC
Pharmaceutical Preparations
$182.62
-0.76% 1D
Market Cap $286.1B
TTM Revenue $62.4B
Forward P/E 16.3x
Beta / 30D Vol 0.04β · 32% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 32.0 Fund 38.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 58.3 · SMA20: $180.75 · SMA50: $169.68
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $4.71 · SMA50: $4.82

6-Pillar Scorecard Institutional Category Breakdown (AZN 5 – 1 CING)

Columns: Metric · AZN · CING
1. Valuation Multiples AZN
Forward P/E 16.3x N/M
Trailing P/E 26.1x N/M
PEG Ratio 1.33x N/M
EV / Revenue 4.6x N/M
2. Growth & Scale AZN
Revenue Growth (YoY) +6.7% +0.0%
Earnings Growth (YoY) +23.5% +0.0%
TTM Revenue (USD) $62.4B N/A
Market Cap $286.1B $62.5M
3. Profitability & Quality AZN
Gross Margin 81.8% N/A
Operating Margin 25.8% 0.0%
Net Profit Margin 17.7% 0.0%
Return on Equity (ROE) 22.6% -198.7%
4. Balance Sheet & Cash Flow AZN
Cash Generation (TTM) $21.3B EBITDA -$21M
Cash Flow Margin 34.1% EBITDA Mgn N/A
Net Cash / Leverage $33.35 Book/Sh · 22.6% ROE $22M Net Cash
Dividend Yield 1.75% None (0.00%)
5. Options & Positioning CING
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 20.3% (8th %ile) 111.1% (16th %ile)
Put/Call OI Skew Thin ADR Chain 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat AZN
OpEx & R&D Intensity 56.0% of Rev ($34.9B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AZN (9) vs CING (0)
Institutional Metric AZN CING Criterion Row Edge
Market Capitalization
Scale
$286.1B $62.5M Larger Scale AZN
Trailing P/E Ratio
Valuation
26.1x N/M Lower Multiple AZN
Forward P/E Ratio
Valuation
16.3x N/M Lower Multiple AZN
Revenue Growth (YoY)
Growth
+6.7% +0.0% Higher Growth AZN
Operating Margin (TTM)
Profitability
25.8% 0.0% Higher Margin AZN
Net Profit Margin
Profitability
17.7% 0.0% Higher Margin AZN
Return on Equity (ROE)
Capital Efficiency
22.6% -198.7% Higher ROE AZN
52-Week Range Position
Momentum
49% ($153–$213) 18% ($3–$12) Stronger Trend AZN
Beta / 30D Volatility
Risk Regime
0.04β · 32% Vol 1.13β · 117% Vol Lower Realized Risk AZN
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$62.4B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.33x PEG · 4.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$21.3B EBITDA ($33.35 Book/Sh · 22.6% ROE) -$21M ($22M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AZN +2.21 pp
AZN: +11.38% · CING: +9.17%
3M Horizon AZN +20.39 pp
AZN: +10.71% · CING: -9.68%
6M Horizon CING +9.53 pp
AZN: -1.1% · CING: +8.43%
1Y Horizon CING +33.91 pp
AZN: +2.48% · CING: +36.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AZN vs CING. Trailing 12-month operating profitability (AZN 25.8% vs CING 0.0%) and valuation multiples (AZN 16.3x vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$62.4B
Gross Margin81.8%
Op. Margin25.8%
ROE / Fwd P/E22.6% · 16.3x
CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AZN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.3%
IV Percentile 8th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AZN Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $286.1B market capitalization and 25.8% operating margin.
OpEx & R&D Reinvestment 56.0% of Rev ($34.9B)
90D Engineering Disclosures 0 Published
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AZN vs CING Key Questions & Quantitative Answers

As of Nov 17, 2026, AstraZeneca PLC (AZN) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AZN carries a Unified Composite Score of 44.8/100 (HOLD) at $182.62 (16.3x Forward P/E, 25.8% operating margin), whereas CING carries 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: AZN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.3); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AZN leads the Growth & Scale pillar: AZN posts +6.7% YoY revenue growth and +23.5% YoY earnings growth on $62.4B TTM revenue (81.8% gross margin, 25.8% operating margin), compared with CING at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AZN generates $62.4B in USD-normalized revenue versus N/A for CING. In operating R&D and SG&A reinvestment, AZN deploys 56.0% of Rev ($34.9B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CING.

AZN screens cheaper on headline valuation multiples. AZN trades at 16.3x Forward P/E, 26.1x Trailing P/E, 1.33x PEG, and 4.6x EV/Revenue (34.1% EBITDA margin), whereas CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AZN (22.6% ROE) versus CING (-198.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AZN carries 20.3% implied volatility (8th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.04β · 32% Vol realized risk). By comparison, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.